| Note |
New from Rhone-Poulenc research. Largactil 1952. Nozinan 1959. Piportil L4 new standard of effectiveness in neuroleptic therapy. Piportil L4 improved control over a wide range of schizophrenic symptoms. Piportil L4 is a new molecule with potent antipsychotic activity, weak sedative properties, and a longer duration of action than any other depot neuroleptic. Effective against residual symptoms. Relieves the major target symptoms of chronic schizophrenia, as well as emotional withdrawal, conceptual disorganization, uncooperativeness, unusual thought content, blunted affect and other residual symptoms which may persist with other neuroleptic agents. Improves symptoms in many patients regardless of previous medication. Patients already stabilized on other neuroleptics showed significant improvement when treated with Piportil L4. Sustained effectiveness. There has been no evidence of decreasing effectiveness in long term maintenance therapy. Most patients remain improved and stable, with few depressive symptoms after long-term use. Treatment with Piportil L4 could result in fewer relapses, and a better chance of social reintegration. Well tolerated. Fewer extrapyramidal side effects than depot fluphenazines. "All other side effects were rare (less than 7%)." There is no evidence of long-term toxicity, and the injection was well tolerated locally. Rapid control over the range of schizophrenic symptoms. Piportil L4. Improved control, simple transition. Treatment can begin immediately. After discontinuing previous antipsychotic medication, an initial dose of 50-100 mg may be administered. If necessary, the dose is increased by increments of 25 mg every 2 or 3 weeks. |
